• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic beats The Street in Q4, Hugo robot wins IDE

Medtronic beats The Street in Q4, Hugo robot wins IDE

May 27, 2021 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) had much to tout with its pipeline as it released Street-beating fourth-quarter results.

CEO Geoff Martha announced to analysts that FDA has granted the company’s much-anticipated Hugo robot an investigational device exemption approval.

Medtronic is preparing to commence its Expand Uro trial in the U.S. to study Hugo in urologic procedures, Martha said during today’s earnings call, transcribed by Seeking Alpha.

Meanwhile, renal denervation appears to be back as a promising treatment for hypertension. Medtronic expects to release its On Med pivotal trial results later this year, likely at the TCT Conference in November. Martha thinks the results are “likely to be one of the most highly anticipated events in medtech this year.”

CFO Karen Parkhill added: “Two of our largest opportunities are surgical robotics and renal denervation. We’re purposely making significant investments in them to ensure we fully capitalize on the multi-billion dollar opportunities ahead.”

Medtronic posted profits of $1.4 billion, or $1 per share, on sales of $8.2 billion for the three months ended April 30, 2021, for a more-than doubled bottom line on sales growth of 36.5% year-over-year.

Adjusted to exclude one-time items, earnings per share were $1.50, 8¢ ahead of Wall Street, where analysts were looking for sales of $8.1 billion.

Medtronic saw growth across its four business segments, with its neuroscience business leading the way at revenue increases of 54%. Cardiovascular (45.1%), medical surgical (20.9%) and diabetes (13.5%) followed. (This was the first time that Medtronic reported under its new corporate structure — the result of a major restructuring.)

The company also announced a 9% dividend increase, raising its quarterly amount to 63¢ per share. Plus the company plans to boost its R&D spend 10% in its new fiscal year, which CEO Geoff Martha touted as the largest dollar increase in research spending in the companies history.

“We’re ultra-focused on accelerating our topline growth, and we’re making incremental investments to put us in a place to drive a sustainable, higher level of growth than you have historically come to expect from Medtronic,” Martha said.

Medtronic’s markets have returned to near normal, pre-COVID growth rates, Martha said.

Medtronic now expects to log adjusted EPS of between $5.60 and $5.75 across fiscal 2022. The company set its sales guidance for growth of approximately 9%, affected by about $400 million to $500 million.

MDT shares were mostly flat at $126.22 apiece by late afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was also up a bit.

Executive editor Chris Newmarker contributed to this report. 

Filed Under: Business/Financial News, Cardiovascular, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Surgical, Surgical Robotics, Wall Street Beat Tagged With: Medtronic

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy